Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

AstraZeneca and GSK Partner with Suppliers to Procure Renewable Power in China

Credit:Goldwind

AstraZeneca and GSK, along with 10 other pharmaceutical companies, have formed a collaboration to procure renewable electricity for their operations in China. The initiative, which involves suppliers including Takeda and several others, is expected to unlock approximately 225GWh of renewable electricity annually. This will power facilities engaged in the research, development, and manufacturing of medicines across the country.

The renewable electricity is sourced from a combination of wind and solar energy and will serve manufacturing sites in the Chinese provinces of Jiangxi, Liaoning, Tianjin, and Zhejiang. This latest agreement follows a similar deal announced in January 2024, which covered other regions such as Beijing, Guangdong, Jiangsu, and Shanghai. Together, the two agreements represent a significant step forward in the industry's push to decarbonize its operations in China.

The collaboration builds on the success of a previous, industry-first multi-party agreement, convened through the Sustainable Markets Initiative. This initiative was initially established by AstraZeneca, Lonza, Novartis, Novo Nordisk, and Roche. The expansion of this program is expected to save approximately 250,000 tonnes of carbon dioxide equivalents (CO2e), doubling the impact of adoption within the sector.

AstraZeneca and GSK are joined in this effort by nine pharmaceutical suppliers, including Lianhe Aigen, ICON, Porton Pharma Solutions, and Aurisco. The initiative marks the first time that companies from across the global healthcare value chain, including local suppliers, have come together in China to support decarbonization efforts in the healthcare manufacturing sector.

The healthcare sector is responsible for about 5% of global greenhouse gas emissions, with over half of those emissions originating from manufacturing supply chains in Asia, particularly in China and India. By switching to renewable power, the initiative aims to reduce the sector's environmental footprint while improving energy security and cost predictability.

“We are thrilled to be co-leading this collaboration with the Sustainable Markets Initiative, which aims to enable our suppliers to access renewable energy,” said Lisa Martin, Chief Procurement Officer at GSK. “This deal demonstrates the power of partnerships in driving meaningful change, supporting business resilience, ensuring energy security, and improving cost predictability in the long term.

Tony Pusic, SVP Regional Supply, Asia Pacific, AstraZeneca, added, “AstraZeneca is delighted to see the platform we jointly established for the collective purchase of renewable power in China expand. Now suppliers and industry partners can contribute to decarbonization in this major market for medicines R&D and manufacturing.

Add a comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Keep Up to Date with the Most Important News

By pressing the Subscribe button, you confirm that you have read and are agreeing to our Privacy Policy and Terms of Use